Syndax Pharmaceuticals’ revumenib was granted FDA orphan designation as a treatment of acute leukemias of ambiguous lineage, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
Questions or Comments about the article? Write to editor@tipranks.com